Fred Grossman
Patrimonio netto: 13 062 $ in data 31/05/2026
Patrimonio netto: 13 062 $ in data 31/05/2026
Dr. Fred Grossman is a President & Chief Medical Officer at Coya Therapeutics, Inc. Dr. Grossman was previously employed as a Chief Medical Officer by Empyrean Neuroscience, Inc., a Chief Medical Officer by Mesoblast Ltd., a Chief Medical Officer by Mesoblast, Inc., a President & Chief Medical Officer by Glenmark Pharmaceuticals Ltd., a President & Chief Medical Officer by Glenmark Pharmaceuticals Inc., USA, a Head-Clinical Development & Medical Affairs by Sunovion Pharmaceuticals, Inc., and a Global Head-Medical Affairs Organization by Bristol Myers Squibb Co. He also served on the board at Reunion Neuroscience, Inc. He received his undergraduate degree from Hahnemann University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/05/2026 | 2.710 ( 0,01% ) | 13 062 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| COYA THERAPEUTICS, INC. | Presidente | 17/07/2023 |
| Società | Posizione | Fine |
|---|---|---|
Empyrean Neuroscience, Inc.
Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Direttore Tecnico/Scientifico/R&S | 01/01/2023 |
| MESOBLAST LIMITED | Direttore Tecnico/Scientifico/R&S | 02/02/2022 |
| GLENMARK PHARMACEUTICALS LIMITED | Presidente | 01/01/2019 |
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Presidente | 01/08/2018 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01/10/2015 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes biopharmaceutical products | Health Technology |
Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
Mesoblast Ltd.
Mesoblast Ltd. BiotechnologyHealth Technology Engages in the development and commercialization of biological and adult stem cells products | Health Technology |
Hahnemann University
Hahnemann University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc., USA Pharmaceuticals: MajorHealth Technology Manufactures and distributes generic pharmaceutical products | Health Technology |
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that focuses on research and development of therapies to enhance the function of regulatory T cells | Health Technology |
Empyrean Neuroscience, Inc.
Empyrean Neuroscience, Inc. Pharmaceuticals: OtherHealth Technology Engages in genetic engineering of fungi and plants to create neuroactive therapeutics | Health Technology |
Reunion Neuroscience, Inc.
Reunion Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale